11:33 PM EST, 11/02/2026 (MT Newswires) -- Coloplast (COLO-B.CO) set its financial guidance for fiscal 2027 and lowered its midterm growth targets through fiscal 2030. For 2027, the Danish medical device company expects organic revenue growth of 5% to 7% and reported revenue growth of between 7% and 9%, according to a Monday filing. Coloplast also lowered its annual organic revenue growth target through fiscal 2030 to 5% to 7% from 7% to 8%, citing changes to US biologics reimbursement, healthcare pricing pressures, and inflation.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.